Jeffrey Nau, Oyster Point Pharma CEO
FDA OKs an inhaled version of smoking cessation drug Chantix — for a common eye disease
Oyster Point Pharma now has its first FDA-approved product — Tyrvaya. And the biotech has taken a unique route to get there by using an old …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
